555
70224226014562119
Ces8507936014570127174
Urol10497936014578115180208
2024;12827936014562121178235258
28(2):15657936014562121154212242264
69–8818557936014561120183247308
PŘEHLEDOVÉ852207016974156235334409485586692777855
ČLÁNKY1754207016981154252352436525
prognostické85089801316296155217277338380417441491539593
a1478898013151
terapeuticko-indikační1564898013135881211742362923523874114625095686056316917527768238779279871011
markery2610898013192143176225279312366
dlaždicobuněčného850104801316186137184245269321380443504565621673734790851913
karcinomu17991048013147101135184208269330424484
penisu23191048013162119180204246306
(penile2661104801313093150211235259315
squamous8501198013141102160210301360419460
cell13441198013149101125148
carcinoma,15271198013149100132180203262321412462482
SCC)20431198013152115174205
na22831198013159109
histologické,2426119801315982122158215240299360383433479532550
imunohistochemické8501348013123110166223280338360398433488537594646733755803847898
a17691348013149
molekulární18391348013188145168220265323345393424482503
úrovni.2363134801315788144191249271290
Ačkoliv26731348013163110154210233254303
WHO8501498013190161235
klasifikuje1112149801314772122163185212239285344367421
pSCC15611498013160110173231
na18201498013159109
HPV-asociovaný19561498013169125181213263304363414437496545596655702
a26851498013150
HPV‑27631498013169124181213
-independentní,850164801313357116176230291346405466520579612671694713
vliv158816480131507497147
HPV17601648013170125182
statutu1967164801314177128161220254313
na23061648013159108
prognózu2440164801316194151213272331374434
je2899164801312377
podle8501798013160120180203256
řady1128179801313283142191
studií1341179801314176134194216238
a16011798013150
našich16731798013158107147169218276
dat19711798013159108141
sporný.21341798013141100160192251298312
V24681798013156
naší25461798013158107147170
studii2737179801314176134194216239
byl8501948013160106129
zjištěn100019480131436688126160211268
negativní12881948013158110170218250272321379400
prognostický1709194801316091147207264321361395417465509560
vliv229019480131497293142
nádorového24531948013157106164222253309357408465523
grade850209801316092143204258
buddingu11342098013160120180241264322383441
na16012098013159108
celkové17352098013149101125171229278331
přežití2092209801316194146191215249273
(overall2390209801312985135187220271294317
survi‑2733209801314198131185209243
val,8502248013150101124142
OS)10212248013174124153
i12022248013123
CSS.12542248013163115165185
Nádorový14672248013170121181240273331380434
budding19292248013161120180241264323383
byl23402248013161109134
u25022248013159
SCC25892248013151114173
aso‑2790224801315091150186
ciován851239801314972131180231290
s11672398013141
metastatickým12332398013190145179229270306357390413462509562653
postižením19122398013160121162197220265318377399489
regionálních2427239801313285146169228288338361419442491550
lymfatických850254801312371161189239272294342388439487544
uzlin.14162548013157102125147204223
Prognostický1661254801315485141202259317357392414463508560
význam22422548013149101148206255343
infiltrace2607254801312380106132154188220270318369
imunitními8502698013123115175235259294355378470494
buňkami13802698013161122182230283375398
u18142698013159
pSCC19092698013162112177237
zkoumá2182269801314593153213305356
jen2574269801312479139
málo27492698013191143167227
relevantních850284801313388113168220273334368429453504565
studií.1451284801314279140202226250271
V17582848013157
naší18512848013160112154178
studii2065284801314279140203227251
byl23522848013162112137
řídký/chy‑2525284801313458121169223260306367416451
bějící8502998013161116139161210233
lymfocytární1112299801312473164193251302354392443475535558
lem1699299801312478168
signifikantně1896299801314163124182205232259305357416449508562
asociovaný2487299801315091150201224283332383442489
s8503148013141
kratším922314801314781132165208231321
OS12743148013174124
i14293148013123
CSS.14833148013163116165186
Mutovaný17003148013185144178236285336395442
profil2173314801316194151179205228
p5324323148013161113164
koreluje26273148013147104138190214272295349
s8503298013140
agresivním9113298013149108139190230251300358380468
fenotypem1399329801312980138195227278338392480
a18993298013149
nepříznivou19693298013158111170201224267325347396452509
prognózou2499329801316092148207264322364420477
u8503448013158
mnoha9373448013190149208268318
typů1283344801313486148207
nádorů15193448013159109169228261321
včetně1868344801315098150184243297
pSCC.21943448013160110173232252
V24743448013156
naší25583448013159109150172
práci2759344801316093145194217
jsme850359801312465155211
potvrdili10963598013161122156211245305328352375
jeho1506359801312478138199
negativní17403598013159114176227261285336397420
prognostický2195359801316295154216276336378414438488535589
do‑28193598013160120157
pad8503748013161112172
na10463748013159109
OS11783748013174124
i13253748013123
CSS.13723748013162115165185
Vysoká15803748013156107148207255307
nádorová19103748013159109169229262319369420
mutační23533748013190148183234283342365
nálož27413748013159109132191235
(tumor850389801312961120211270304
mutational11883898013190149183234268291350410460483
burden,17063898013160120152212266325344
TMB)20843898013152138194221
byla23403898013161109133183
asociova‑2558389801315091150201224283332384418
ná8504048013159109
s9874048013141
kratším1057404801314681132165207230320
OS,14054048013174125144
s15774048013141
vysokou16474048013149102144203251309368
expresí20434048013153102163197249291313
programmed2384404801316194152213245296386476531592
death8504198013160115165199258
ligandu1143419801312447108158218279338
115164198013154
(PD-L1)1605419801312985156193245291313
a19534198013150
HPV/p1620384198013170126183217276323371
negativitou.24444198013159114176227261284335359394452512532
Nález8504348013171121145199246
časté11304348013150101142178231
PD-L113964348013155126163215261
pozitivity16924348013161122166190225248299323358411
u21384348013159
HPV-negativních22324348013169125183215276331393443477500551612635685744
nádorů8504498013158106165223255313
s11844498013140
vysokým12454498013149101141199245296386
TMB16524498013150134188
ilustruje1861449801312345102141175207265287339
onkogenezi22214498013158116161218277330387440484507
pSCC27494498013160108169227
v8504648013151
souvislosti9384648013142104165218243285309371414451476
s14504648013143
chronickým15294648013151112146206268292344392447542
zánětem,21074648013146100161217253307401421
vysokým25654648013151106150212261316411
množstvím8504798013193154215261306344399425518
získaných1404479801314671112160214276325375436
mutací18774798013192153189242294318
a22314798013151
produkcí2319479801316297157220281329380404
neo‑27594798013161117179217
antigenů8504948013151110144168229284344402
(PD-L1)1287494801313086157194246293315
a16374948013150
činí1722494801315073133156
z19134948013145
nemocných19934948013160115206266318378426475535
s25634948013142
HPV-in‑26404948013170126184216241301336
dependentními8505098013160115176232291352407467500560583673697
SCC15815098013152115175
kandidáty1791509801314699158219243303354387440
anti-PD-1/PD-L122665098013150110143167201259329366414447504575612664710
léčby.850524801312377128188236251
Popsané11265248013155112173214266324379
znaky,15305248013144104154200253267
jako1822524801312473120177
je2024524801312478
nádorový21275248013159108169228261319368421
budding,25735248013161120181241264323383403
lymfocytární850539801312372164193251301353392443475535558
infiltrát1432539801312382108135158192225276309
a17655398013150
p53,18395398013161113164182
korelují20455398013147105138190214272295318
s23875398013141
přežitím2453539801316093146191215249272362
vý‑28395398013150103137
znamněji8505548013144103153242300354376399
než12715548013158112157
pT14505548013160105
stadium,1577554801314176126186208266355374
histopatologický1973554801315981121156212273324356413437495556579628673726
grade2721554801315991142202255
nebo8505698013159113174234
morfologický11105698013191150183216275299358419442491538591
subtyp1727569801314198159193245307
karcinomu2061569801314698130178201260319410468
penisu.25555698013161116175198238296315
KLÍČOVÁ8525984014770132164236320392464
SLOVA13435984014762123207279351
Dlaždicobuněčný850614801317093141184241262309364423480536588636693738
karcinom1607614801314696126172193250307395
penisu,20216148013160113170191229284301
HPV,23426148013168121176187
prognóza,2548614801316091147206262319361410428
budding,8506298013161119178238259317376395
tumor1269629801313491180239271
infiltrující1564629801312380106133154188219278300321369391
lymfocyty.1979629801312371162189247296347384436449
SUMMARY8526584014762143243345423493561
Zavillová10006748013159109157180202223281330379
N.,1408674801317089107
Hrudka15436748013170101159219264315
J.,188667480131385674
Zachoval19886748013159109158215274322372394
R.2410674801315677
Squamous25156748013151111168217305364422461
cell8506898013149100122144
carcinoma1014689801314998129176197255313402451
of1485689801315886
penis15926898013160114172193232
–18446898013155
etiology,1919689801315386108166189246306355367
immune23076898013123111200256314367
micro‑26946898013190111159191247282
environment8507048013153111158181212269328416470527559
and14337048013150108167
prognostic1624704801316193150210268326366401423471
markers.21197048013190139170216268299340360
Penile10007198013154103159180201252
cancer1270719801314997153200249279
is1568719801312260
a16477198013149
relatively1714719801313282104151181202250300322368
rare2101719801313280110160
malignancy22807198013188135156177234290337393440490
with27887198013178100132188
a8507348013150
highly932734801315981140198221269
variable12337348013150100131154203262286339
prognosis.1604734801316193150210268327367388427447
The20837348013151111165
most22807348013190149189224
important25367348013123112172231263300350408440
indicator850749801312483144167217268302360393
of1277749801315989
cancer14007498013150101161211264296
specific17307498013142103159210233260287337
survival21017498013142100133187211262313337
(CSS)2471749801313092145195224
is2729749801312464
the2827749801313494149
involvement850764801312381128185208257309398451509541
of1412764801315886
regional1519764801313384145166224283331354
lymph1894764801312371161221279
nodes,21947648013159117178231271289
which25047648013180138160208266
may27917648013190139185
not3203898013159117149
be3372898013161115
identified350789801312382134192223245271298350410
during3937898013160117148171228287
clinical42448980131497192150171219269291
examination4555898013153101150238260317366398420477536
or511189801315890
by5221898013161108
conventional32031048013149106164212264322355377435494543565
imaging38011048013123112161221243301361
methods.41941048013191144178236295355395415
For46411048013151108141
that4814104801313493142174
reason,5020104801313385133173232291309
new32031198013159113193
prognostic3428119801316294151212271330370406428477
and39381198013150109169
therapeutic4140119801313493146178229289344402436458507
markers46801198013191140172219271303345
of5057119801315988
pe‑51781198013161116151
nile3203134801315981103155
squamous33891348013141100157206295353411450
cell38701348013149100122144
carcinoma4044134801314999130177199256315404453
(SCC)4527134801312977139197227
are4785134801314981132
currently49471348013150107138170222280312334382
being32031498013161116139197258
investigated3494149801312381129182223258281341391424475537
at4064149801315083
the4180149801313493147
histological,4360149801316082122157214238297358380429480503521
immuno‑49141498013123113203261320379415
histochemical3203164801315981120154210260317370460481530579602
and38351648013149107167
molecular40321648013190148171224274331353402433
level.4495164801312376125177199218
Although4743164801316486120178236294353411
the5184164801313492145
WHO32031798013189158230
classifies3453179801314970118158197218243269322361
penile38341798013160113171192213265
SCC41191798013151112169
into4308179801312279110166
HPV-associated44931798013169123178208256295334392441462510541592651
and51641798013149106165
HPV-independent,32031948013169124179210233291350403463517575634687745777796
the4027194801313492145
prognostic4201194801316092149209267325365400422470
impact47001948013123111171221269306
of5034194801315987
HPV51491948013170124180
status3203209801314176125157215254
remains3487209801313284173221243301340
questionable38562098013160117170210245267325383432492515568
according4453209801315098145201233291313370429
to4912209801313490
several5031209801314194143195226276298
studies3203224801314174131190211262302
and35242248013150107165
our37092248013157114145
data.38742248013159107138187205
In4099224801312380
our41982248013158115146
study,4363224801314174131190237250
a46322248013149
negative47012248013158110170218249271319370
prog‑5090224801316092147207239
nostic32032398013159117157192214262
effect3489239801315382112164214250
of3763239801315887
tumour3874239801313492180239297328
grade4226239801316091141201253
budding45032398013161119179238260318377
on49042398013159117
overall50452398013159107159190240262284
survival3203254801314197128181203252302324
(OS)3547254801312999148176
and37432548013150107166
CSS39302548013162113162
was41122548013179128168
found.4300254801312986143201260278
Tumour45992548013151100189247304335
budding49552548013160118177236258315374
has32032698013159108147
been33782698013161115169227
associated3633269801315089129187237259307339390450
with41112698013180102135194
the4332269801313492146
metastatic45052698013190144177226266301350382404453
involve‑4986269801312380127184207257308343
ment32032848013189141198229
of3451284801315886
regional3556284801313283142163220277325347
lymph3922284801312370159217275
nodes42162848013159116175227266
in4502284801312279
penile46002848013160113170191212264
SCC.48832848013151112168187
A50892848013164
few5172284801312980157
relevant3203299801313284107159208258316347
studies3575299801314175133192214267307
have39062998013159108156207
investigated4138299801312380127179219254276335384416467527
the4689299801313492146
prognostic4859299801316092149209267325365400422470
significance3203314801314162121179201227253302352409458509
of3736314801315887
immune38473148013123112201258315369
cell42403148013149100122144
infiltration4408314801312381106133154188219269302324381440
in4872314801312380
pSCC.49773148013160109170228247
In5248314801312381
our32033298013158115145
study,3367329801314175131190237249
a36363298013149
non-brisk/absent37043298013159116173205265297318357401443488546585637694725
lymphocyte4449329801312369158217274331380430466516
infiltrate4984329801312379104130152184215264295345
was32033448013180130170
significantly3405344801314163122180202228255303353411443466514
associated3952344801315090130188238260308341392452
with44373448013179102136194
shorter4663344801314299158190227278310
OS50053448013174124
and51613448013150109168
CSS.32033598013162112160178
Mutated34013598013184140173222253303362
p5337823598013160110159
profile3960359801316091147172198219271
correlates42503598013149104135166217239286317367407
with46763598013178100133190
aggressive48853598013149108166196247286325345394444
phenotype32033748013161119172230289321372433487
and37213748013150107167
poor39183748013161120179211
prognosis4160374801316193149209267325365387426
in4616374801312381
many47273748013191139197243
tumour5001374801313491180239297328
types3203389801313486148202243
including3479389801312381130153210270292351411
penile39223898013161116175197219272
SCC.42273898013151114172192
Our44513898013175134165
data46493898013160110142192
confirmed48743898013150106165191218249340394455
its3203404801312357100
negative33354048013160114175225257280330383
prognostic3750404801316294152213272331371407429478
impact42614048013123113174224274311
on46044048013159119
both47564048013161121154213
OS50024048013174125
and51594048013151110170
CSS.32034198013163115163182
High3418419801316991150208
tumour3658419801313492182240298330
mutational40204198013190147181231263285343402451473
burden45254198013161119151209262320
(TMB)4877419801312984169224251
was51604198013179129169
associated3203434801314988126183231252299330379438
with36604348013178100132189
shorter3867434801314197153184220270300
OS,41864348013173121138
with43434348013178100132188
high4550434801315879137193
programmed4762434801315990145204234283370457508567
death32034498013161116165199259
ligand3495449801312447107158217279
138074498013155
(PD-L1)3896449801312985156193245291312
expression42424498013154103165199252293335357416477
and47524498013151111172
HPV/p1649584498013171126184218276323371
negativity.32034648013158110169217249270318340373423436
The36584648013151110162
PD-L138394648013154122157206249
positivity41084648013160118157178210231280302334385
enrichment45124648013153109140162209266353405462493
in5024464801312379
HPVnegative5123464801316812117632034798013159112172221253275325376
tumours3611479801313492181239297329369
harboring40124798013159108139200259291314371431
high4475479801315980139197
TMB47044798013151136191
illustrates492747980131234566123163197229279311362402
pSCC32034948013161109171229
oncogenesis34594948013158117165221282335392445486507546
in4032494801312381
association4140494801315089129187237259307339361419477
with46444948013180102136194
chronic48654948013149107138194253274323
in‑5215494801312380114
flammation,3203509801312753102191280328361383440499517
high3749509801315880139197
amount39755098013150139197255313344
of4348509801315987
acquired4464509801315098155213234266317377
mutations,48705098013190147181231263285342401440459
and32035248013149106165
neoantigen33875248013159111169218275306328386438495
(PD-L1)3902524801312982149184234277297
production.4219524801316091147206262310346367424482500
This47385248013151110131170
discovery4927524801315981119167222269320351402
suggests3203539801314197155214267306340382
that3604539801313492140172
patients37955398013161110142164216273304345
with41605398013179101134192
HPV-independent43725398013168122177207230287346398457511568627679737768
SCC51605398013151112169
could32035548013149105163185244
be34785548013161115
suitable3624554801314197119152202262285338
candidates3993554801314998156216237297345377428469
for4493554801312886118
anti-PD-1/PD-L146415548013150108140162195251320356402434489558593644688
treatment.3203569801313466117165197287340398430449
In3677569801312381
summary,3783569801314197186275324355407420
tumour4228569801313492180239297328
budding,45815698013161119178238260317376395
tumour5001569801313491180239297328
lymphocytic3203584801312371162221280338387438476498546
infiltration3776584801312380106132154187219269301323381440
and42425848013150108168
p5344365848013161112162
show4624584801314299157235
a48865848013150
stronger4963584801314175107164222282334366
correlation32035998013149105138170222245294326348406465
with37015998013179102136194
survival3927599801314198130183206255305328
outcomes42875998013159117151197254344397438
compared47575998013149105196255306337389450
to5239599801313490
factors3203614801312979128164220252293
such3525614801314198146204
as3758614801315090
pT38776148013161105
stage,4011614801314175125184237254
histopathological4294614801315981120154210270320353411469492550610632680730752
grade5075614801316092141201254
or3203629801315991
morphological33186298013190148180241299357381439499521569619641
subtype3983629801314197157190241302356
in4363629801312380
penile44686298013160114172194216269
carcinoma.4761629801314999130177198256314404453472
KEY32046584014770134206
WORDS343765840147105189260345408
HPV32036748013169124179
status,3414674801314176126158216255274
prognosis,3720674801316193149210267326366387426445
squamous41976748013141100158206295354412451
cell46806748013149100123145
carcinoma,4857674801314999130177199256315404453472
tumor3203689801313492181239271
budding,34986898013161119178238260317377395
tumor3917689801313492180239271
infiltrating4212689801312380106133154188219269301324381440
cells.46776898013149100122144183202
………320371840147120240360